Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748837 · ClinicalTrials.gov registry record · Phase 1
A Study of ERY974 in Patient With Advanced Solid Tumors
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02748837 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 29 participants.
The verdict
NCT02748837, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Interventions
- DRUG ERY974
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02748837
The ClinicalTrials.gov registry entry for NCT02748837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ERY974 is the first listed.
NCT02748837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02748837 about?
NCT02748837 is a clinical study titled "A Study of ERY974 in Patient With Advanced Solid Tumors". This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tum...
What is the current status of trial NCT02748837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-08. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02748837?
The interventions under investigation include: ERY974 (DRUG).
Who is sponsoring clinical trial NCT02748837?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.